Thu Sep 19 08:06:30 UTC 2024: ## BioXcel Therapeutics (BTAI) Sees Short Interest Decline, Beats Earnings Estimates

**New York, NY** – BioXcel Therapeutics, Inc. (NASDAQ: BTAI) experienced a notable drop in short interest during August, according to data released by MarketBeat News. The company’s short interest fell by 6.9% to 680,500 shares as of August 31st, indicating a potential shift in investor sentiment.

Despite the decline in short interest, BioXcel’s stock opened at $0.64 on Thursday, remaining below its 52-week high of $5.62. However, the company recently exceeded analysts’ expectations in its earnings report for the quarter ending August 6th, posting a $0.55 beat in earnings per share.

Analysts are forecasting a loss of $1.84 per share for BioXcel in the current year. Notably, several institutional investors have recently adjusted their holdings of BTAI. Point72 Asia Singapore Pte. Ltd., Armistice Capital LLC, XTX Topco Ltd, Rosalind Advisors Inc., and Vanguard Group Inc. have all made changes to their positions in the company.

BioXcel Therapeutics is a commercial-stage biopharmaceutical company focusing on developing innovative medicines for neuroscience and immuno-oncology. Their approach utilizes artificial intelligence to re-innovate existing approved drugs or clinically validated product candidates, using big data and machine learning algorithms to identify new therapeutic indices.

Investors will be closely monitoring BioXcel’s future performance, particularly in light of the recent earnings beat and declining short interest.

Read More